+

US20070134316A1 - Soft capsule of butylphthalide and a process for preparing the same - Google Patents

Soft capsule of butylphthalide and a process for preparing the same Download PDF

Info

Publication number
US20070134316A1
US20070134316A1 US11/445,832 US44583206A US2007134316A1 US 20070134316 A1 US20070134316 A1 US 20070134316A1 US 44583206 A US44583206 A US 44583206A US 2007134316 A1 US2007134316 A1 US 2007134316A1
Authority
US
United States
Prior art keywords
butylphthalide
oil
capsule
soft capsule
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/445,832
Inventor
Jianqing Li
Min Bai
Wenmin Guo
Surui Chen
Liyun Liu
Guirong Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shijiazhuang Pharma Group Zhongqi Pharmaceutical Technology Co Ltd
Shijiazhuang Pharma Group NBP Pharmaceutical Co Ltd
Original Assignee
Shijiazhuang Pharma Group Zhongqi Pharmaceutical Technology Co Ltd
Shijiazhuang Pharma Group NBP Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shijiazhuang Pharma Group Zhongqi Pharmaceutical Technology Co Ltd, Shijiazhuang Pharma Group NBP Pharmaceutical Co Ltd filed Critical Shijiazhuang Pharma Group Zhongqi Pharmaceutical Technology Co Ltd
Assigned to SHIJIAZHUANG PHARMA GROUP NBP PHARMACEUTICAL CO., LTD., SHIJIAZHUANG PHARMA, GROUP ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. reassignment SHIJIAZHUANG PHARMA GROUP NBP PHARMACEUTICAL CO., LTD. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: BAI, MIN, CHEN, SURUI, GUO, WENMIN, LI, JIANQING, LIU, LIYUN, ZHOU, GUIRONG
Publication of US20070134316A1 publication Critical patent/US20070134316A1/en
Priority to US13/092,610 priority Critical patent/US8609137B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a soft capsule of butylphthalide and a process for preparing the same.
  • Butylphthalide is the main component of the celery and the seeds thereof. It may be obtained not only by direct extraction from the natural plant celery seed oil, but also by synthesis.
  • Chinese Patent No. 98125618.X discloses the use of levo-butylphthalide in the manufacture of a medicament against thrombosis and platelet aggregation, and clearly shows that levo-butylphthalide has the effect on regulating the function of NOS-NO-cGMP system and the metabolism of arachidonic acid in neural cells after cerebral ischemia.
  • Chinese Patent No. 98125618.X discloses the use of levo-butylphthalide in the manufacture of a medicament against thrombosis and platelet aggregation, and clearly shows that levo-butylphthalide has the effect on regulating the function of NOS-NO-cGMP system and the metabolism of arachidonic acid in neural cells after cerebral ischemia.
  • butylphthalide an oily liquid with strong flavour of celery, is represented by the following chemical formula:
  • the soft capsule as a relatively novel dosage form, is particularly advantageous in the preparation of oily active ingredients into oral formulations, in which the active pharmaceutical ingredient is uniformly distributed in the diluent and fractional dose is accurate. Furthermore, the soft capsule has round and smooth shape, and is easy to be swallowed, which increases the compliance of patients.
  • the present inventors have developed a novel butylphthalide formulation, which is a soft capsule of butylphthalide, by taking advantages of physical and chemical properties of butylphthalide and the characteristics of soft capsules.
  • An object of the present invention is to provide a soft capsule of butylphthalide.
  • the soft capsule of butylphthalide according to the present invention is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil in an ratio of about 1:0-10 by weight. Furthermore, an appropriate antioxidant, dibutylcarboxyl toluene, may also be added into the drug-containing oil.
  • butylphthalide as used herein means racemic butylphthalide, levo-butylphthalide, or dextro-butylphthalide, which are all oily liquid.
  • the vegetable oil may be one of sesame oil, corn oil, peanut oil, soybean oil, almond oil, peach kernel oil, cottonseed oil, sunflower seed oil, olive oil, or the mixture thereof.
  • the capsule wall material is essentially composed of a capsule wall matrix, a plasticizer and water in a weight ratio of about 1:0.2 ⁇ 0.4: 0.8 ⁇ 1.3.
  • An appropriate preservative such as ethyl p-hydroxybenzoate or methyl p-hydroxybenzoate, may also be added into the capsule wall material.
  • the capsule wall matrix may be one of gelatin and arabic gum, or the mixture thereof.
  • the plasticizer may be one of glycerol and sorbitol, or the mixture thereof.
  • the soft capsule of butylphthalide according to the present invention may be prepared by using the standard process for preparing soft capsules, such as hand compression molding, rotary compression molding or dropping molding. Generally, a compression process such as rotary compression molding using an automated rotary capsule machine controlled at 40-50° C. may be used, so that each capsule contains a pharmaceutically effective amount of butylphthalide.
  • the soft capsule is prepared as a novel formulation of butylphthalide according to the present invention.
  • a soft capsule can mask the strong and special flavour of butylphthalide, and overcome the difficulties associated with formulating oily active agent into other oral formulation.
  • the soft capsule has round and smooth shape, and is easy to be swallowed, which increases the compliance of patients.
  • the soft capsule of butylphthalide according to the present invention is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil in an preferable weight ratio of about 1:1-8, more preferably about 1:2-5, most preferably about 1:3.5. Furthermore, as an antioxidant, about 0-0.2% of dibutylcarboxyl toluene relative to the weight of drug-containing oil may also be added into the drug-containing oil.
  • the vegetable oil is peanut oil, soybean oil, corn oil, and sesame oil. Most preferably, the vegetable oil is soybean oil.
  • the capsule wall material is essentially composed of a capsule wall matrix, a plasticizer and water, wherein the capsule wall matrix is preferably gelatin, and the plasticizer is preferably glycerol.
  • Components of gelatin solution 100 g of gelatin, 30 g of glycerol, 130 g of water and 200 mg of ethyl p-hydroxybenzoate.
  • Gelatin was added into an appropriate amount of water to permit it to absorb water and swell.
  • Glycerol, ethyl p-hydroxybenzoate and remaining water were added into a melting tank and heated to 70-80° C. After uniformly mixed, the swollen gelatin was added, agitated, melted and incubated for 1-2 hours. The resulting mixture was thus kept standing to allow foams floating up. Then foams were removed by filtering through clean white cloth, and the temperature was kept for use.
  • the gelatin solution was generally formulated at 2.8-3.2 rpm.
  • Preparation of drug-containing oil 100 g of butylphthalide was weighed and thoroughly mixed with 350 g of clear soybean oil, to obtain the drug-containing oil. Compression of soft capsules: The gelatin solution and drug-containing oil were supplied into an automated rotary capsule machine. The temperature was kept at 40-50° C., and soft capsules were compressed, each of which contains 450 mg of drug-containing oil.
  • the preparation procedure was the same as that described in Example 1, except that no vegetable oil was added in the step of preparing drug-containing oil.
  • Each of the soft capsules finally compressed contains 100 mg of drug-containing oil.
  • gelatin solution 100 g of gelatin, 40 g of glycerol, 120 g of water and 200 mg ethyl p-hydroxybenzoate were used.
  • the steps for preparing gelatin solution were the same as that described in Example 1.
  • the preparation procedure was the same as that described in Example 1, except that in the step of preparing the drug-containing oil, 56.25 g of butylphthalide was weighed and thoroughly mixed with 393.75 g of clear peanut oil. Each of the soft capsules finally compressed contains 800 mg of drug-containing oil.
  • gelatin solution 100 g of gelatin, 20 g of glycerol, 80 g of water and 200 mg of ethyl p-hydroxybenzoate were used. The steps for preparing gelatin solution were the same as that described in Example 1.
  • the preparation procedure was the same as that described in Example 1, except that in the step of preparing the drug-containing oil, 90 g of butylphthalide was weighed and thoroughly mixed with 360 g of clear soybean oil. Each of soft capsules finally compressed contains 500 mg of drug-containing oil.
  • the preparation procedure was the same as that described in Example 1, except that in the step of preparing the drug-containing oil, 40.91 g of butylphthalide was weighed and thoroughly mixed with 409.09 g of clear soybean oil. Each of soft capsules finally compressed contains 1100 mg of drug-containing oil.
  • the preparation procedure was the same as that described in Example 1, except that in the step of preparing the drug-containing oil, 50 g of butylphthalide was weighed and thoroughly mixed with 400 g of clear soybean oil. Each of soft capsules finally compressed contains 900 mg of drug-containing oil.
  • the preparation procedure was the same as that described in Example 1, except that in the step of preparing the drug-containing oil, 150 g of butylphthalide was weighed and thoroughly mixed with 300 g of clear soybean oil and 0.45 g of dibutylcarboxyl toluene as an antioxidant. Each of soft capsules finally compressed contains 300.3 mg of drug-containing oil.
  • Example 1 Samples prepared in Example 1 were provided. Time required for complete disintegration of each soft capsule was tested in accordance with the disintegration time assay (Pharmacopoeia of P.R. China, the edition of 2000, Part II, Appendix VA), with 1000 ml of diluted hydrochloric acid (9 to 1000) as solvent, the temperature was controlled at 37 ⁇ 1° C., the lift-and-drop rate of 30 to 32 times per minute, and with a baffle plate when operated. Time required by complete disintegration of each soft capsule was investigated. The disintegration time should not be over 1 hour, and should comply with the corresponding regulations.
  • Tests were performed according to High Performance Liquid Chromatography (Pharmacopoeia of P.R. China, the edition of 2000, Part II, Appendix VD).
  • testing Method Appropriate amount of the content of capsules was sampled, appropriate amount of chloroform was added into it to dissolve, and then methanol was added to supplement the volume. The resulting solution was diluted with methanol to formulate a testing solution containing 0.5 mg of the content per milliliter.
  • Appropriate amount of butylphthalide control was separately and precisely weighed, dissolved with methanol and formulated into a control solution containing 15 ⁇ g of butylphthalide per milliliter. 20 ⁇ l of control solution was accurately injected into the liquid chromatograph and tested according to the method known in the art. The detection sensitivity was adjusted in order to make the peak of the main fraction as high as 10-20% of full range.
  • Control Solution 50 mg of butylphthalide was precisely weighed and placed into a 50 ml measuring flask. The weighed butylphthalide is dissolved with methanol and diluted to the predetermined value of scale, and mixed uniformly. 5 ml of resulting solution was precisely taken and placed into a 50 ml measuring flask, diluted with methanol to the predetermined value of scale, and thus the control solution was obtained.
  • Test Solution Preparation of Test Solution: Appropriate amount of the content in capsules (approximately 50 mg of butylphthalide) was taken and precisely weighed. The weighed content is placed into a 50 ml measuring flask, dissolved with appropriate amount of chloroform, diluted with methanol to the predetermined value of scale and thoroughly mixed. 5 ml of resulting solution was precisely taken and placed into a 50 ml measuring flask, diluted with methanol to the predetermined value of scale, and thus the test solution was obtained.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Formation And Processing Of Food Products (AREA)

Abstract

The present invention discloses a novel soft capsule of butylphthalide and a process for preparing the same. The soft capsule of butylphthalide is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil as the diluent in a weight ratio of about 1:0˜10. The capsule wall material is composed of a capsule wall matrix, a plasticizer and water in a weight ratio of 1:0.2˜0.4:0.8˜1.3. The soft capsule of butylphthalide described in the present invention can mask the strong and special flavour of butylphthalide, and overcome the difficulties associated with formulating oily active ingredient into other oral formulation. The disintegration time of the soft capsule satisfies the requirement of Pharmacopoeia of P.R. China.

Description

    PRIORITY INFORMATION
  • This application is a continuation of International Application No. PCT/CN2004/001411, which was filed on 3 Dec., 2004, which designated the United States and was published in Chinese, and which claims the benefit of Chinese Application CN200310119336.1, filed 5 Dec., 2003.
    • FIELD OF THE INVENTION
  • The present invention relates to a soft capsule of butylphthalide and a process for preparing the same.
    • BACKGROUND OF THE INVENTION
  • Butylphthalide is the main component of the celery and the seeds thereof. It may be obtained not only by direct extraction from the natural plant celery seed oil, but also by synthesis. Chinese Patent No. 98125618.X discloses the use of levo-butylphthalide in the manufacture of a medicament against thrombosis and platelet aggregation, and clearly shows that levo-butylphthalide has the effect on regulating the function of NOS-NO-cGMP system and the metabolism of arachidonic acid in neural cells after cerebral ischemia. Chinese Patent No. 93117148.2 discloses the use of butylphthalide in the manufacture of a medicament for preventing and treating diseases caused by cerebral ischemia in a mammal or human, wherein the butylphthalide has no optically active. Butylphthalide, an oily liquid with strong flavour of celery, is represented by the following chemical formula:
    Figure US20070134316A1-20070614-C00001
  • The soft capsule, as a relatively novel dosage form, is particularly advantageous in the preparation of oily active ingredients into oral formulations, in which the active pharmaceutical ingredient is uniformly distributed in the diluent and fractional dose is accurate. Furthermore, the soft capsule has round and smooth shape, and is easy to be swallowed, which increases the compliance of patients.
    • SUMMARY OF THE INVENTION
  • The present inventors have developed a novel butylphthalide formulation, which is a soft capsule of butylphthalide, by taking advantages of physical and chemical properties of butylphthalide and the characteristics of soft capsules.
  • An object of the present invention is to provide a soft capsule of butylphthalide.
  • The soft capsule of butylphthalide according to the present invention is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil in an ratio of about 1:0-10 by weight. Furthermore, an appropriate antioxidant, dibutylcarboxyl toluene, may also be added into the drug-containing oil.
  • Term “butylphthalide” as used herein means racemic butylphthalide, levo-butylphthalide, or dextro-butylphthalide, which are all oily liquid.
  • The vegetable oil may be one of sesame oil, corn oil, peanut oil, soybean oil, almond oil, peach kernel oil, cottonseed oil, sunflower seed oil, olive oil, or the mixture thereof.
  • The capsule wall material is essentially composed of a capsule wall matrix, a plasticizer and water in a weight ratio of about 1:0.2˜0.4: 0.8˜1.3. An appropriate preservative, such as ethyl p-hydroxybenzoate or methyl p-hydroxybenzoate, may also be added into the capsule wall material.
  • The capsule wall matrix may be one of gelatin and arabic gum, or the mixture thereof.
  • The plasticizer may be one of glycerol and sorbitol, or the mixture thereof.
  • The soft capsule of butylphthalide according to the present invention may be prepared by using the standard process for preparing soft capsules, such as hand compression molding, rotary compression molding or dropping molding. Generally, a compression process such as rotary compression molding using an automated rotary capsule machine controlled at 40-50° C. may be used, so that each capsule contains a pharmaceutically effective amount of butylphthalide.
  • The soft capsule is prepared as a novel formulation of butylphthalide according to the present invention. Such a soft capsule can mask the strong and special flavour of butylphthalide, and overcome the difficulties associated with formulating oily active agent into other oral formulation. Furthermore, the soft capsule has round and smooth shape, and is easy to be swallowed, which increases the compliance of patients.
    • DETAILED DESCRIPTION OF THE INVENTION
  • The soft capsule of butylphthalide according to the present invention is composed of a capsule wall material and a drug-containing oil, wherein the drug-containing oil is essentially composed of butylphthalide and a vegetable oil in an preferable weight ratio of about 1:1-8, more preferably about 1:2-5, most preferably about 1:3.5. Furthermore, as an antioxidant, about 0-0.2% of dibutylcarboxyl toluene relative to the weight of drug-containing oil may also be added into the drug-containing oil.
  • Preferably, the vegetable oil is peanut oil, soybean oil, corn oil, and sesame oil. Most preferably, the vegetable oil is soybean oil.
  • The capsule wall material is essentially composed of a capsule wall matrix, a plasticizer and water, wherein the capsule wall matrix is preferably gelatin, and the plasticizer is preferably glycerol.
  • The following examples are provided for a particular purpose of further illustrating technical features of the present invention, and should not be construed as any limitation to the present invention.
    • EXAMPLE 1 Preparation of Soft Capsules of Butylphthalide
  • Components of gelatin solution: 100 g of gelatin, 30 g of glycerol, 130 g of water and 200 mg of ethyl p-hydroxybenzoate. Gelatin was added into an appropriate amount of water to permit it to absorb water and swell. Glycerol, ethyl p-hydroxybenzoate and remaining water were added into a melting tank and heated to 70-80° C. After uniformly mixed, the swollen gelatin was added, agitated, melted and incubated for 1-2 hours. The resulting mixture was thus kept standing to allow foams floating up. Then foams were removed by filtering through clean white cloth, and the temperature was kept for use. The gelatin solution was generally formulated at 2.8-3.2 rpm.
  • Preparation of drug-containing oil: 100 g of butylphthalide was weighed and thoroughly mixed with 350 g of clear soybean oil, to obtain the drug-containing oil. Compression of soft capsules: The gelatin solution and drug-containing oil were supplied into an automated rotary capsule machine. The temperature was kept at 40-50° C., and soft capsules were compressed, each of which contains 450 mg of drug-containing oil.
  • The soft capsules, compressed with the drug-containing oil by such a ratio, were tested and showed to have moderate shape and size and good content homogeneity. Results of the test were as following:
    TABLE 1
    Caps. Caps. Caps. Caps. Caps. Caps. Caps. Caps. Caps. Caps.
    Sample 1 2 3 4 5 6 7 8 9 10
    Content 99.12 98.08 100.02 99.47 99.32 101.38 98.65 98.76 99.25 98.47
    (%)
    Range of 98.08-101.38
    content (%)
    Standard 0.93
    deviation
    (%)
    • EXAMPLE 2 Preparation of the Soft Capsules of Butylphthalide
  • The preparation procedure was the same as that described in Example 1, except that no vegetable oil was added in the step of preparing drug-containing oil. Each of the soft capsules finally compressed contains 100 mg of drug-containing oil.
    • EXAMPLE 3 Preparation of Soft Capsules of Butylphthalide
  • Preparation of gelatin solution: 100 g of gelatin, 40 g of glycerol, 120 g of water and 200 mg ethyl p-hydroxybenzoate were used. The steps for preparing gelatin solution were the same as that described in Example 1.
  • Preparation of drug-containing oil: 225 g of butylphthalide was weighed and thoroughly mixed with 225 g of clear peanut oil, to obtain the drug-containing oil. Compression of soft capsules: The procedure was the same as that described in Example 1, except that each of the soft capsules finally compressed contains 200 mg of drug-containing oil.
  • The soft capsules, compressed with the drug-containing oil by such a ratio, were tested, and results were as following:
    TABLE 2
    Caps. Caps. Caps. Caps. Caps. Caps. Caps. Caps. Caps. Caps.
    Sample 1 2 3 4 5 6 7 8 9 10
    Content 98.33 96.08 99.42 101.73 94.37 100.31 92.65 98.79 102.01 95.78
    (%)
    Range of 92.65-102.01
    content (%)
    Standard 3.14
    deviation (%)
    • EXAMPLE 4 Preparation of Soft Capsules of Butylphthalide
  • The preparation procedure was the same as that described in Example 1, except that in the step of preparing the drug-containing oil, 56.25 g of butylphthalide was weighed and thoroughly mixed with 393.75 g of clear peanut oil. Each of the soft capsules finally compressed contains 800 mg of drug-containing oil.
  • The soft capsules, compressed with the drug-containing oil in such a ratio, were tested, and results were as following:
    TABLE 3
    Caps. Caps. Caps. Caps. Caps. Caps. Caps. Caps. Caps. Caps.
    Sample 1 2 3 4 5 6 7 8 9 10
    Content 100.03 99.08 99.42 101.73 98.57 100.31 99.55 98.99 100.11 99.98
    (%)
    Range of content 98.57-101.73
    (%)
    Standard deviation 0.88
    (%)
    • EXAMPLE 5 Preparation of Soft Capsules of Butylphthalide
  • Preparation of gelatin solution: 100 g of gelatin, 20 g of glycerol, 80 g of water and 200 mg of ethyl p-hydroxybenzoate were used. The steps for preparing gelatin solution were the same as that described in Example 1.
  • Preparation of drug-containing oil: 45 g of butylphthalide was weighed and thoroughly mixed with 405 g of clear peanut oil, to obtain the drug-containing oil. Compression of soft capsules: The procedure was the same as that described in Example 1, except that each of soft capsules finally compressed contains 1000 mg drug-containing oil.
    • EXAMPLE 6 Preparation of Soft Capsules of Butylphthalide
  • The preparation procedure was the same as that described in Example 1, except that in the step of preparing the drug-containing oil, 90 g of butylphthalide was weighed and thoroughly mixed with 360 g of clear soybean oil. Each of soft capsules finally compressed contains 500 mg of drug-containing oil.
    • EXAMPLE 7 Preparation of Soft Capsules of Butylphthalide
  • The preparation procedure was the same as that described in Example 1, except that in the step of preparing the drug-containing oil, 40.91 g of butylphthalide was weighed and thoroughly mixed with 409.09 g of clear soybean oil. Each of soft capsules finally compressed contains 1100 mg of drug-containing oil.
    • EXAMPLE 8 Preparation of Soft Capsules of Butylphthalide
  • The preparation procedure was the same as that described in Example 1, except that in the step of preparing the drug-containing oil, 50 g of butylphthalide was weighed and thoroughly mixed with 400 g of clear soybean oil. Each of soft capsules finally compressed contains 900 mg of drug-containing oil.
    • EXAMPLE 9 Preparation of Soft Capsules of Butylphthalide
  • The preparation procedure was the same as that described in Example 1, except that in the step of preparing the drug-containing oil, 150 g of butylphthalide was weighed and thoroughly mixed with 300 g of clear soybean oil and 0.45 g of dibutylcarboxyl toluene as an antioxidant. Each of soft capsules finally compressed contains 300.3 mg of drug-containing oil.
    • EXAMPLE 10 Test of Butylphthalide Content, Related Materials and Disintegration Time
  • Determination Method
  • A) Disintegration Time: Samples prepared in Example 1 were provided. Time required for complete disintegration of each soft capsule was tested in accordance with the disintegration time assay (Pharmacopoeia of P.R. China, the edition of 2000, Part II, Appendix VA), with 1000 ml of diluted hydrochloric acid (9 to 1000) as solvent, the temperature was controlled at 37±1° C., the lift-and-drop rate of 30 to 32 times per minute, and with a baffle plate when operated. Time required by complete disintegration of each soft capsule was investigated. The disintegration time should not be over 1 hour, and should comply with the corresponding regulations.
  • B) Related Materials: Tests were performed according to High Performance Liquid Chromatography (Pharmacopoeia of P.R. China, the edition of 2000, Part II, Appendix VD).
  • Testing Method: Appropriate amount of the content of capsules was sampled, appropriate amount of chloroform was added into it to dissolve, and then methanol was added to supplement the volume. The resulting solution was diluted with methanol to formulate a testing solution containing 0.5 mg of the content per milliliter. Appropriate amount of butylphthalide control was separately and precisely weighed, dissolved with methanol and formulated into a control solution containing 15 μg of butylphthalide per milliliter. 20 μl of control solution was accurately injected into the liquid chromatograph and tested according to the method known in the art. The detection sensitivity was adjusted in order to make the peak of the main fraction as high as 10-20% of full range. 20μl of testing solution was accurately taken and tested according to the same method. Chromatographic spectrum was recorded for two times of the retention time of the main fraction peak in chromatography. If impurities presented in chromatographic spectrum, the area sum under the peak of each impurity (with the exception of the peak of solvent) was calculated, should be not more than the area of that of control solution (3.0%).
  • C) Determination of butylphthalide content: The content was determined by High Performance Liquid Chromatography (Pharmacopoeia of P.R. China, the edition of 2000, Part II, Appendix VD).
  • Chromatographic Condition And System Suitability Test: Silica gel bonded with octodecyl silane was used as packing, methanol-water (65:35) was used as mobile phase with a flow rate of 1.0 ml/min. The detection was performed at the wavelength of 280 nm. Theoretical plate number of butylphthalide should be not less than 1500. The degree of separating butylphthalide from impurities should comply with related regulations.
  • Preparation of Control Solution: 50 mg of butylphthalide was precisely weighed and placed into a 50 ml measuring flask. The weighed butylphthalide is dissolved with methanol and diluted to the predetermined value of scale, and mixed uniformly. 5 ml of resulting solution was precisely taken and placed into a 50 ml measuring flask, diluted with methanol to the predetermined value of scale, and thus the control solution was obtained.
  • Preparation of Test Solution: Appropriate amount of the content in capsules (approximately 50 mg of butylphthalide) was taken and precisely weighed. The weighed content is placed into a 50 ml measuring flask, dissolved with appropriate amount of chloroform, diluted with methanol to the predetermined value of scale and thoroughly mixed. 5 ml of resulting solution was precisely taken and placed into a 50 ml measuring flask, diluted with methanol to the predetermined value of scale, and thus the test solution was obtained.
  • Testing Method: 20 μl of control solution and 20 μl of test solution separately were precisely sampled and injected into the liquid chromatograph, and then tested according to the method known in the art. The chromatographic spectrum was recorded, and the content of butylphthalide (C12H14O2) was calculated with peak area in accordance with external standard method.
  • The experimental data were represented as following:
    TABLE 4
    Content of
    Related
    Test condition Content material Disintegration
    Environment Time Appearance (%) (%) time
    Initial Day 0 Yellow, transparent soft 98.8 0.61  4′50″
    capsule
    Accelerating  1 mon. Yellow, transparent soft 98.7 0.66  6′45″
    test capsule
     2 mon. Yellow, transparent soft 99.3 0.63 14′10″
    capsule
     3 mon. Yellow, transparent soft 98.4 0.62 28′30″
    capsule
     6 mon. Yellow, transparent soft 99.0 0.58 49′52″
    capsule
    Sample at  1 mon. Yellow, transparent soft 98.6 0.63  5′15″
    room capsule
    temperature  3 mon. Yellow, transparent soft 98.8 0.67  8′35″
    capsule
     6 mon. Yellow, transparent soft 99.4 0.66  9′45″
    capsule
    12 mon. Yellow, transparent soft 99.1 0.62 17′50″
    capsule
    18 mon. Yellow, transparent soft 98.5 0.64 27′25″
    capsule
    24 mon. Yellow, transparent soft 98.5 0.65 29′35″
    capsule
  • Although frequently soft capsules have the problem of unqualified disintegration due to the prolonged time of storage, as shown in the accelerating test and long period test on the present soft capsules, the wall of the soft capsule aged quickly with heating treatment and disintegration time changed significantly but still remained less than 60 minutes, which complied with related regulations of Pharmacopoeia of P.R. China, the edition of 2000. Various parameters, such as product appearance, the content and related materials and the like all complied with the standard, with a valid period up to 2 years.

Claims (13)

1. A soft capsule comprising butylphthalide, characterized in that it is comprised of a capsule wall material and a drug-containing oil, wherein the drug-containing oil comprises butylphthalide and a vegetable oil in a weight ratio in the range of 1:0 to 1:10.
2. A soft capsule comprising butylphthalide, characterized in that it is comprised of a capsule wall material and a drug-containing oil, wherein the drug-containing oil consists essentially of butylphthalide and a vegetable oil in a weight ratio in the range of 1:0 to 1:10.
3. The soft capsule of claim 1, wherein the weight ratio of butylphthalide to vegetable oil is in the range of 1:1 to 1:8.
4. The soft capsule of claim 3, wherein the weight ratio of butylphthalide to the vegetable oil is in the range of 1:2 to 1:5.
5. The soft capsule of claim 4, wherein the weight ratio of butylphthalide to the vegetable oil is 1:3.5.
6. The soft capsule of claim 1, wherein the vegetable oil is selected from the group consisting of sesame oil, corn oil, peanut oil, soybean oil, almond oil, peach kernel oil, cotton seed oil, sunflower seed oil, olive oil and mixtures thereof.
7. The soft capsule of claim 1, wherein the butylphthalide is selected from the group consisting of racemic butylphthalide, levo-butylphthalide and dextro-butylphthalide.
8. The soft capsule of claim 1, wherein the drug-containing oil further comprises 0-0.2% of dibutylcarboxyl toluene as an antioxidant relative to the weight of drug-containing oil.
9. The soft capsule of claim 1, wherein the capsule wall material comprises a capsule wall matrix, a plasticizer and water in a weight ratio of 1:0.2-0.4:0.8-1.3.
10. The soft capsule of claim 1, wherein the capsule wall material consists essentially of a capsule wall matrix, a plasticizer and water in a weight ratio of 1:0.2-0.4:0.8-1.3.
11. The soft capsule of claim 9, wherein the capsule wall matrix is selected from the group consisting of gelatin, Arabic gum, and a mixture of gelatin and Arabic gum.
12. The soft capsule of claim 9, wherein the plasticizer is selected from the group consisting of glycerol, sorbitol, and a mixture of glycerol and sorbitol.
13. The soft capsule of claim 9, wherein the capsule wall material further comprises a preservative.
US11/445,832 2003-12-05 2006-06-02 Soft capsule of butylphthalide and a process for preparing the same Abandoned US20070134316A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/092,610 US8609137B2 (en) 2003-12-05 2011-04-22 Soft capsule of butylphthalide and a process for preparing the same

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN200310119336.1 2003-12-05
CNB2003101193361A CN1257711C (en) 2003-12-05 2003-12-05 Butyl benzene phthalein soft capsule and its preparation method
PCT/CN2004/001411 WO2005053658A1 (en) 2003-12-05 2004-12-03 Butylphthalide soft gel capsule and its preparatin procedure

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2004/001411 Continuation WO2005053658A1 (en) 2003-12-05 2004-12-03 Butylphthalide soft gel capsule and its preparatin procedure

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/092,610 Continuation US8609137B2 (en) 2003-12-05 2011-04-22 Soft capsule of butylphthalide and a process for preparing the same

Publications (1)

Publication Number Publication Date
US20070134316A1 true US20070134316A1 (en) 2007-06-14

Family

ID=34638049

Family Applications (4)

Application Number Title Priority Date Filing Date
US10/581,370 Abandoned US20080020034A1 (en) 2003-12-05 2004-12-03 Butylphtualide Soft Gel Capsule and Its Preperation Procedure
US11/445,832 Abandoned US20070134316A1 (en) 2003-12-05 2006-06-02 Soft capsule of butylphthalide and a process for preparing the same
US12/195,360 Abandoned US20080305163A1 (en) 2003-12-05 2008-08-20 Butylphthalide soft gel capsule and its preparation procedure
US13/092,610 Expired - Lifetime US8609137B2 (en) 2003-12-05 2011-04-22 Soft capsule of butylphthalide and a process for preparing the same

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/581,370 Abandoned US20080020034A1 (en) 2003-12-05 2004-12-03 Butylphtualide Soft Gel Capsule and Its Preperation Procedure

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/195,360 Abandoned US20080305163A1 (en) 2003-12-05 2008-08-20 Butylphthalide soft gel capsule and its preparation procedure
US13/092,610 Expired - Lifetime US8609137B2 (en) 2003-12-05 2011-04-22 Soft capsule of butylphthalide and a process for preparing the same

Country Status (15)

Country Link
US (4) US20080020034A1 (en)
EP (1) EP1702612B1 (en)
JP (1) JP4634394B2 (en)
KR (1) KR100761437B1 (en)
CN (1) CN1257711C (en)
AT (1) ATE427104T1 (en)
AU (1) AU2004294254B2 (en)
BR (1) BRPI0417339C8 (en)
CA (1) CA2549498C (en)
DE (1) DE602004020381D1 (en)
HK (1) HK1090302A1 (en)
MX (1) MXPA06006401A (en)
NO (1) NO338520B1 (en)
RU (1) RU2322976C1 (en)
WO (1) WO2005053658A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8726005B2 (en) 2009-12-10 2014-05-13 George Mason Intellectual Properties, Inc. Website matching based on network traffic

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100471494C (en) * 2005-12-24 2009-03-25 石药集团中奇制药技术（石家庄）有限公司 Butylphthalide dripping pills and preparation method
CN104971056A (en) * 2006-01-24 2015-10-14 株式会社·R-技术上野 Soft-gelatin Capsule Formulation
CN101342152B (en) * 2007-07-10 2010-10-13 石药集团中奇制药技术（石家庄）有限公司 Butylbenzene phthalein tablet and preparation method thereof
CN102058560B (en) * 2010-12-30 2013-07-24 张家界茅岩莓有限公司 Dihydromyricetin soft capsules and preparation method thereof
CN102178643B (en) * 2011-04-29 2014-05-14 石药集团恩必普药业有限公司 Microemulsion transdermal gel agent of butylphthalide or derivative thereof, and preparation method thereof
CN103169685B (en) * 2011-12-23 2018-03-06 石药集团中奇制药技术（石家庄）有限公司 A kind of butylphenyl phthaleine controlled release preparation and preparation method thereof
CN107648222A (en) * 2012-06-06 2018-02-02 石药集团中奇制药技术（石家庄）有限公司 A kind of butylphthalide medicine active composition and preparation method thereof
CN102716103B (en) * 2012-07-02 2013-12-18 西安力邦制药有限公司 2, 2', 6, 6'-tetraisopropyl-4, 4'-2-biphenol soft capsule and method for preparing same
CN109939102B (en) * 2013-06-13 2022-05-17 石药集团中奇制药技术（石家庄）有限公司 Pharmaceutical composition containing butylphthalide and borneol and application thereof
CN106606498A (en) * 2016-07-25 2017-05-03 山东诚创医药技术开发有限公司 Butylphthalide soft capsule
CN106580959B (en) * 2017-01-10 2019-04-23 山东省立医院 A kind of butylphthalalnitrate soft capsule for relieving acute ischemic stroke
CN109432042B (en) * 2018-12-24 2022-04-22 石药集团恩必普药业有限公司 Soft capsule shell and preparation method thereof
CN112336700B (en) * 2019-08-08 2023-12-01 河北菲尼斯生物技术有限公司 Stable butylphthalide-containing medicament and preparation method thereof
CN114073694B (en) * 2020-08-14 2024-03-12 北京科莱博医药开发有限责任公司 Butylphthalide preparation and preparation method thereof
KR102523186B1 (en) 2020-11-19 2023-04-18 (주)알피바이오 Composition for animal-based chewable soft capsule and animal-based chewable soft capsule using the same
KR102294072B1 (en) 2020-11-19 2021-08-26 (주)알피바이오 Composition for plant-based chewable soft capsule and plant-based chewable soft capsule using the same
CN113975242A (en) * 2021-10-14 2022-01-28 山东诚创蓝海医药科技有限公司 Butylphthalide soft capsule for improving oral bioavailability
CN115469039B (en) * 2022-10-28 2024-04-26 成都施贝康生物医药科技有限公司 Butylphthalide and detection method of related substances thereof
CN115453014B (en) * 2022-10-28 2024-04-19 成都施贝康生物医药科技有限公司 Detection method of butylphthalide and related substances thereof

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
US4366145A (en) * 1981-06-24 1982-12-28 Sandoz, Inc. Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation
US4525306A (en) * 1981-09-21 1985-06-25 Asama Chemical Co., Ltd. Method for prevention of oxidation of oils and fats and soft capsules containing the treated oils and fats
US6096338A (en) * 1994-03-16 2000-08-01 R. P. Scherer Corporation Delivery systems for hydrophobic drugs
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
US20020090393A1 (en) * 2000-03-01 2002-07-11 Ke Liu Soft gelation capsule containing angelica oil and preparation thereof
US20030087034A1 (en) * 1999-02-12 2003-05-08 Lts Lohmann Therapie-Systeme Ag Method for producing film-type dosage
US20060166931A1 (en) * 2002-08-21 2006-07-27 Niu Zhan-Qi Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparation and the use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7510104A (en) * 1975-08-27 1977-03-01 Akzo Nv PROCESS FOR THE PREPARATION OF AN ORAL ACTIVE PHARMACEUTICAL PREPARATION.
FR2608456B1 (en) * 1986-12-18 1993-06-18 Mero Rousselot Satia MICROCAPSULES BASED ON GELATIN AND POLYSACCHARIDES AND PROCESS FOR OBTAINING THEM
JPH01199958A (en) * 1987-07-23 1989-08-11 Tsumura & Co Novel phthalide derivative and its production
CN1129908A (en) 1993-06-25 1996-08-28 美因坎普营销私人有限公司 Therapeutic agent
AUPO990397A0 (en) * 1997-10-22 1997-11-13 R.P. Scherer Holdings Pty Ltd Clear solutions of herbal extracts
CN1086942C (en) * 1998-12-18 2002-07-03 中国医学科学院药物研究所 Application of butyl phthalide in preparing medicines curing thrombosis and thrombocyte coagulation
CN1375288A (en) * 2002-05-13 2002-10-23 周桂荣 Composite medicine for treating cerebrovascular diseases

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
US4366145A (en) * 1981-06-24 1982-12-28 Sandoz, Inc. Soft gelatin capsule with a liquid ergot alkaloid center fill solution and method of preparation
US4525306A (en) * 1981-09-21 1985-06-25 Asama Chemical Co., Ltd. Method for prevention of oxidation of oils and fats and soft capsules containing the treated oils and fats
US6096338A (en) * 1994-03-16 2000-08-01 R. P. Scherer Corporation Delivery systems for hydrophobic drugs
US20030087034A1 (en) * 1999-02-12 2003-05-08 Lts Lohmann Therapie-Systeme Ag Method for producing film-type dosage
US6193999B1 (en) * 1999-03-01 2001-02-27 Banner Pharmacaps, Inc. Gum acacia substituted soft gelatin capsules
US20020090393A1 (en) * 2000-03-01 2002-07-11 Ke Liu Soft gelation capsule containing angelica oil and preparation thereof
US20060166931A1 (en) * 2002-08-21 2006-07-27 Niu Zhan-Qi Clathrates of butylphtualide with cyclodextrin or its derivatives, a process for their preparation and the use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8726005B2 (en) 2009-12-10 2014-05-13 George Mason Intellectual Properties, Inc. Website matching based on network traffic

Also Published As

Publication number Publication date
CA2549498A1 (en) 2005-06-16
NO20062895L (en) 2006-09-04
WO2005053658A1 (en) 2005-06-16
JP4634394B2 (en) 2011-02-16
BRPI0417339C1 (en) 2021-05-25
AU2004294254B2 (en) 2008-02-07
AU2004294254A1 (en) 2005-06-16
NO338520B1 (en) 2016-08-29
US8609137B2 (en) 2013-12-17
JP2007513097A (en) 2007-05-24
US20120052117A1 (en) 2012-03-01
BRPI0417339B1 (en) 2017-12-19
CA2549498C (en) 2011-07-12
CN1257711C (en) 2006-05-31
KR100761437B1 (en) 2007-10-04
US20080305163A1 (en) 2008-12-11
CN1623542A (en) 2005-06-08
EP1702612A1 (en) 2006-09-20
ATE427104T1 (en) 2009-04-15
BRPI0417339A (en) 2007-02-21
KR20060105013A (en) 2006-10-09
EP1702612A4 (en) 2006-12-20
MXPA06006401A (en) 2007-11-13
DE602004020381D1 (en) 2009-05-14
HK1090302A1 (en) 2006-12-22
RU2322976C1 (en) 2008-04-27
BRPI0417339B8 (en) 2020-06-02
RU2006122207A (en) 2008-01-10
EP1702612B1 (en) 2009-04-01
BRPI0417339C8 (en) 2022-02-01
US20080020034A1 (en) 2008-01-24
WO2005053658A8 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
US8609137B2 (en) Soft capsule of butylphthalide and a process for preparing the same
Vanherweghem et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs
Wu et al. Pharmacokinetics of (±)‐,(+)‐, and (−)‐gossypol in humans and dogs
US20060251743A1 (en) Composition for inducing sleep comprising essential oils as active ingredients, a percutaneous pharmaceutical agent comprising thereof, and a process for producing thereof
CH676201A5 (en)
CN101322694A (en) Piclofenac potassium sustained release tablets and preparing technique thereof
CN105030716B (en) Caffeinum pharmaceutical combination and preparation method thereof
WO2008022557A1 (en) Liquid composition of sirolimus
CN100574761C (en) Mycophenolate mofetil dry suspension
CN109833309A (en) Memantine is sustained microplate capsule and preparation method thereof
CN101439083B (en) Detection method of Chinese medicine soft capsules for clearing wind heat and clearing nasal passage
CN107281167B (en) A kind of benzonatate soft capsule and preparation method thereof
CN103919718B (en) A kind of vitamin A palmitate eye drop and its production and use
CN110016007A (en) Cyclic diphenylheptane compound, its preparation method, its application, medicine and dietary supplement
MXPA06006269A (en) Butylphthalide soft gel capsule and its preparatin procedure
JPH054925A (en) Soft capsule preparation of alpha calcidiol
CN112156074A (en) Arbidol hydrochloride spray and preparation method thereof
CN109954129A (en) A kind of pharmaceutical composition and its preparation containing Pu Kana peptide
CN1228960A (en) Soft capsule for treating thrombus and its preparing process
US20080063704A1 (en) Stable gabapentin compositions
RU2200003C1 (en) Solid medicinal form of terbinafine hydrochloride
CN112823793A (en) Transdermal patch containing donepezil and preparation method thereof
CN114392289A (en) Medicine composition for treating diabetes with vascular complications
CN115381791A (en) Flunarizine hydrochloride pharmaceutical composition
CN111380967A (en) Method for measuring atropine related substances

Legal Events

Date Code Title Description
AS Assignment

Owner name: SHIJIAZHUANG PHARMA, GROUP ZHONGQI PHARMACEUTICAL

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, JIANQING;BAI, MIN;GUO, WENMIN;AND OTHERS;REEL/FRAME:018846/0186

Effective date: 20060710

Owner name: SHIJIAZHUANG PHARMA GROUP NBP PHARMACEUTICAL CO.,

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:LI, JIANQING;BAI, MIN;GUO, WENMIN;AND OTHERS;REEL/FRAME:018846/0186

Effective date: 20060710

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载